Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Organ-on-a-Chip World Congress & 3D-Culture 2017

Kristin Fabre's Biography

Kristin Fabre, Microphysiological Systems Lead, Drug Safety & Metabolism, AstraZeneca

Dr. Fabre is part of Drug Safety and Metabolism, AstraZeneca as the Microphysiological Systems Development and Implementation Lead, working with several key AZ members to develop how to best utilize MPS technology for drug development and screening. Prior to joining AZ, she was the Scientific Program Manager for the Microphysiological Systems (or Organs-on-Chips) Initiative at NIH National Center for Advancing Translational Sciences (NCATS). This role included providing oversight on all MPS cooperative agreements, including members from FDA, DARPA, NIH and several academic institutions across the United States in addition to building public-private partnerships. Dr. Fabre received her BS in Biology from the University of Wyoming, followed by her MS and PhD from Colorado State University in Cell and Molecular Biology. Prior to joining NCATS, she completed her NIH National Cancer Institute postdoctoral fellowship, emphasizing research in cancer biology, DNA repair and radiation biology. During her time at the NCI, Dr. Fabre was highly involved with training programs and was Chair of the NCI Fellows and Young Investigators Steering Committee and created the NCI Fellows Outreach Committee.

Kristin Fabre Image

Implementing Microphysiological Systems Into AstraZeneca Research Projects

Monday, 10 July 2017 at 16:00

Add to Calendar ▼

Microphysiological systems (MPS) hold much promise for providing a physiologically-relevant human model that could be utilized for toxicity and efficacy screening during drug development.  The AstraZeneca MPS Center of Excellence was established in the Fall of 2016, with a goal to 1) develop an effective strategy that identifies best-fit MPS platforms, 2) gain confidence in these models and finally, 3) implement into active projects if the technologies prove to be advantageous over current methods.  The purpose of this presentation will illustrate how we have put this strategy into practice, highlighting AstraZeneca-MPS examples.  Furthermore, we recognize the need to collaborate with government and other industry partners to catalyze the refinement, evolution and eventually, commercialization of MPS, which will also be discussed.

Add to Calendar ▼2017-07-10 00:00:002017-07-11 00:00:00Europe/LondonOrgan-on-a-Chip World Congress and 3D-Culture 2017Organ-on-a-Chip World Congress and 3D-Culture 2017 in Boston, USABoston,